Comparison in metabolic control and treatment satisfaction with continuous subcutaneous insulin infusion and multiple daily injections in children at onset of type 1 diabetes mellitus

Submission date 29/04/2007	Recruitment status No longer recruiting	 Prospectively registered Protocol
Registration date 03/07/2007	Overall study status Completed	 [] Statistical analysis plan [X] Results
Last Edited 16/05/2019	Condition category Nutritional, Metabolic, Endocrine	Individual participant data

Plain English summary of protocol

Not provided at time of registration

Contact information

Type(s) Scientific

Contact name Dr Lars Skogsberg

Contact details

Pediatric Clinic Gävle Hospital Gävle Sweden S-80187 -

lars.skogsberg@lg.se

Additional identifiers

EudraCT/CTIS number Nil known

IRAS number

ClinicalTrials.gov number

Nil known

Secondary identifying numbers N/A

Study information

Scientific Title

Comparison in metabolic control and treatment satisfaction with continuous subcutaneous insulin infusion and multiple daily injections in children at onset of type 1 diabetes mellitus

Study objectives

To compare treatment satisfaction with Continuous Subcutaneous Insulin Infusion (CSII) and Multiple Daily Injections (MDI) in newly diagnosed diabetic children and adolescents. Our outcome measurements are metabolic control, safety and treatment satisfaction.

Ethics approval required

Old ethics approval format

Ethics approval(s) Uppsala University (Sweden), approved on 11th October 2001 (ref: Ups dnr 01-347)

Study design Open, randomized, parallel group study.

Primary study design Interventional

Secondary study design Randomised controlled trial

Study setting(s) Not specified

Study type(s) Not Specified

Participant information sheet

Health condition(s) or problem(s) studied Type 1 diabetes mellitus

Interventions

Group 1: Continuous subcutaneous insulin infusion for 24 months Group 2: Multiple daily insulin injections for 24 months

Intervention Type

Drug

Phase

Not Specified

Drug/device/biological/vaccine name(s)

insulin

Primary outcome measure

The following were measured at baseline, 1 month, 6, 12 and 24 months:

1. Metabolic control (HbA1c)

2. Treatment satisfaction (Qestionnaires Diabetes Treatment Satisfaction Questionnaire [DTSQ])

3. Safety (Registration of hospitalization for ketoacidosis [defined as pH <7.3] and major hypoglycemic episodes and/or technical problems)

Secondary outcome measures

The following were measured at baseline, 1 month, 6, 12 and 24 months:

1. BMI

- 2. Isulin requirment
- 3. Adverse events
- 4. C-petide
- 5. insulin-like growth factor-1 (IGF-1)
- 6. Binding proteins

Overall study start date

01/12/2001

Completion date 31/05/2006

Eligibility

Key inclusion criteria

Children and adolescents (age 7 to 17 years) with newly diagnosed (within 3 weeks) type 1 diabetes mellitus.

Participant type(s) Patient

Age group Child

Lower age limit 7 Years

Upper age limit 17 Years

Sex Not Specified

Target number of participants 72 patients **Total final enrolment** 72

Key exclusion criteria Other relavent diseases.

Date of first enrolment 01/12/2001

Date of final enrolment 31/05/2006

Locations

Countries of recruitment Sweden

Study participating centre Pediatric Clinic Gävle Sweden S-80187

Sponsor information

Organisation County of Gävleborg (Sweden)

Sponsor details Gävle Hospital Gävle

Sweden S-80187

Sponsor type

Government

Website http://www.lg.se

Funder(s)

Funder type

Government

Funder Name Research and Development Center, County of Gävleborg (Sweden)

Funder Name Foundation for Children with Diabetes (Barndiabetesfonden) (Sweden)

Results and Publications

Publication and dissemination plan

Not provided at time of registration

Intention to publish date

Individual participant data (IPD) sharing plan

IPD sharing plan summary

Not provided at time of registration

Study outputs

Output type	Details	Date created	Date added	Peer reviewed?	Patient-facing?
Results article	results	01/10/2008	16/05/2019	Yes	No